Detalhe da pesquisa
1.
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Blood
; 121(23): 4655-62, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23613521
2.
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Lancet Haematol
; 2(3): e118-28, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26687797
3.
Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
Cancer Genet
; 208(11): 571-4, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26382622
4.
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Clin Lymphoma Myeloma Leuk
; 14(2): 155-162.e1, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24332214
5.
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia.
Leuk Lymphoma
; 56(12): 3452-4, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25926060